A study set out to uncover the impact that Tralokinumab, a fully human antibody, may have on treating Staphylococcus aureus colonization of the skin and systemic levels of inflammatory biomarkers in patients with atopic dermatitis.
Learn more at the Journal of the American Academy of Dermatology.